RETEVMO 80 mg/1

RETEVMO 80 mg tablets are a prescription medication used to treat certain types of cancer. This oral medication is designed to target specific genetic mutations, offering a targeted approach to cancer therapy.

RETEVMO 80 mg tablets are primarily used in the treatment of advanced or metastatic cancers that harbor specific genetic alterations. These tablets are often prescribed for patients with non-small cell lung cancer, thyroid cancer, or other solid tumors with RET gene fusions or mutations. RETEVMO is part of a class of drugs known as kinase inhibitors, which work by blocking the activity of abnormal proteins that can drive cancer growth. Patients should consult their healthcare provider to determine if RETEVMO is suitable for their specific condition.

Common effects of RETEVMO 80 mg tablets may include fatigue, diarrhea, and increased liver enzymes. Some patients may also experience changes in taste, dry mouth, or constipation. These effects can vary in severity and duration, and patients should report any persistent or severe symptoms to their healthcare provider.

RETEVMO 80 mg tablets should be handled with care and stored as directed. Patients should avoid crushing or chewing the tablets unless instructed otherwise. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Pregnant women or those planning to become pregnant should discuss the potential risks with their healthcare provider before starting RETEVMO.

RETEVMO 80 mg tablets may interact with certain medications, including strong CYP3A inhibitors and inducers. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions. Alcohol consumption should be discussed with a healthcare provider, as it may affect the efficacy or safety of RETEVMO.